Anti-Matrix protein 1 antibody [GA2B] (ab22396)
Key features and details
- Mouse monoclonal [GA2B] to Matrix protein 1
- Suitable for: Flow Cyt, IHC-P, WB, ICC/IF
- Reacts with: Species independent
- Isotype: IgG1
Overview
-
Product name
Anti-Matrix protein 1 antibody [GA2B]
See all Matrix protein 1 primary antibodies -
Description
Mouse monoclonal [GA2B] to Matrix protein 1 -
Host species
Mouse -
Tested applications
Suitable for: Flow Cyt, IHC-P, WB, ICC/IFmore details -
Species reactivity
Reacts with: Species independent -
Immunogen
Tissue, cells or virus corresponding to Matrix protein 1. Influenza A/ Puerto Rico/ 8/ 34 (H1N1) and A/Bangkok/ 1/ 79 (H3N2) viruses
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.50
Preservative: 0.09% Sodium azide
Constituent: PBS -
Concentration information loading...
-
Purity
SDS-PAGE -
Purification notes
>90% IgG content as established by SDS PAGE -
Clonality
Monoclonal -
Clone number
GA2B -
Myeloma
P3x63-Ag8.653 -
Isotype
IgG1 -
Research areas
Associated products
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab22396 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Flow Cyt | (1) |
Use at an assay dependent concentration. PubMed: 20413723
ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody. |
IHC-P |
Use at an assay dependent concentration.
|
|
WB | (1) |
Use at an assay dependent concentration.
|
ICC/IF |
1/100.
|
Notes |
---|
Flow Cyt
Use at an assay dependent concentration. PubMed: 20413723 ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody. |
IHC-P
Use at an assay dependent concentration. |
WB
Use at an assay dependent concentration. |
ICC/IF
1/100. |
Target
-
Relevance
Influenza virus type A matrix protein, also known as M1, is composed of a 252 amino acid sequence and is type-specific in influenza viruses. It is located inside the viral lipid envelope and plays a key role in virus assembly and replication. M1 can be isolated from particles by removing the envelope with detergents and reducing the pH to 4.0. Influenza viruses are a common and widely spread infectious agent. Like many other viruses, influenza virus are constantly undergoing mutations and thereby avoiding the immune system. The Influenza A Virus M proteins form a continuous shell on the inner side of the lipid bilayer, maintaining the structural integrity of the virus particle through hydrophobic interactions. -
Cellular localization
Cytoplasmic -
Alternative names
- M1 antibody
- Matrix Protein 1 antibody
- Matrix Protein I antibody
- Membrane matrix protein M1 antibody
Images
-
Immunocytochemistry/ Immunofluorescence - Anti-Matrix protein 1 antibody [GA2B] (ab22396)Image from Chase GP et al., PLoS Pathog. 2011 Sep;7(9):e1002187. Epub 2011 Sep 1.Fig 4.; doi:10.1371/journal.ppat.1002187; September 1, 2011, PLoS Pathog 7(9): e1002187.Immunofluorescence analysis of HeLa cells staining Influenza A Virus M1 using ab22396.
Cells were treated with either 20 µg/ml Prostaglandin A (PGA) or EtOH vehicle control, 3 hours post infection by Influenza A Virus, then fractionated at 9 hours post infection before analysis by immunofluorescence.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (19)
ab22396 has been referenced in 19 publications.
- Amarelle L et al. Cardiac glycosides decrease influenza virus replication by inhibiting cell protein translational machinery. Am J Physiol Lung Cell Mol Physiol 316:L1094-L1106 (2019). PubMed: 30892074
- Xie X et al. Influenza Vaccine With Consensus Internal Antigens as Immunogens Provides Cross-Group Protection Against Influenza A Viruses. Front Microbiol 10:1630 (2019). PubMed: 31379782
- Kang HJ et al. Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs. PLoS One 14:e0216871 (2019). PubMed: 31246961
- Vashisht S et al. Cross-clade antibody reactivity may attenuate the ability of influenza virus to evade the immune response. Mol Immunol 114:149-161 (2019). PubMed: 31352231
- Desforges JP et al. Environmental contaminant mixtures modulate in vitro influenza infection. Sci Total Environ 634:20-28 (2018). Flow Cyt . PubMed: 29626767